← All indications
Hodgkin Disease
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Drugs by status
Approved for this indication (16)
Phase 4 trials (6)
Phase 3 trials (56)
- allogeneic cord blood
- cyclosporine
- imm01
- vincristine
- panobinostat
- Anti-thymocyte Globulin (Rabbit)
- epoetin
- fludarabine
- sargramostim
- allogeneic hematopoietic stem cells
- vinorelbine
- sirolimus
- azacitidine
- lysergic acid diethylamide
- mycophenolate
- autologous hematopoietic stem cells
- prednisolone
- regn1979
- methotrexate
- oxaliplatin
- aldoxorubicin
- rituximab
- cisplatin
- etoposide
- zanubrutinib
- plerixafor
- moxifloxacin
- dexamethasone
- pembrolizumab
- gemcitabine
- +26 more
Phase 2 trials (201)
- autologous cd19/cd22 chimeric antigen receptor t-cells
- cd70 car-nk
- axicabtagene ciloleucel
- palifermin
- cyanocobalamin
- angiotensin 1-7
- resminostat
- givinostat
- mosunetuzumab
- cd3/cd28 stimulated t cells
- amifostine
- letermovir
- afm13
- abatacept
- carfilzomib
- zarnestra
- lmp-specific cytotoxic t-lymphocytes
- allogeneic cd20 car-t cell
- lentivirus vector ccr5 shrna/trim5alpha/tar decoy-transduced autologous cd34-positive hematopoietic progenitor cells
- abexinostat
- n-(4-hydroxyphenyl)all-trans retinamide
- temsirolimus
- tanespimycin
- pf-04878691
- idelalisib
- autologous lymphocytes
- autologous humanized anti-cd19 and anti-cd20 dual specific car-t cells
- veliparib
- tioguanine
- gen3017
- +171 more
Phase 1 trials (158)
- irinotecan
- inducible regulatory t cells
- morab-004
- th2 cells
- vactosertib
- tg-1501
- geptanolimab
- sd-101
- lmp1/2 ctls
- triapine
- cefepime
- mabel ctls
- abeotaxane
- mt-601
- selinexor
- hydrocortisone
- dr-0201
- anti-cd19 il10 car-nk
- sunitinib
- autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells
- alisertib
- bcl-2 antisense oligonucleotide
- pentamidine
- lirilumab
- mdx-1401
- lvsh5/c46 (cal-1) transduced cd34+ hematopoietic stem cells
- barf1-specific cytotoxic t-lymphocytes
- erlotinib
- tagraxofusp-erzs
- cd30.car-ebvst
- +128 more
Organizations
Organization Involved with Phase 4 Indications (7)
Organization Involved with Phase 3 Indications (90)
- Bristol-Myers Squibb
- Imclone
- Genzyme
- Pfizer
- Novartis
- BeOne Medicines
- Chugai
- Hengrui Therapeutics, Inc.
- Innovent Biologics (Suzhou) Co. Ltd.
- Ortho Biotech, Inc.
- Teva
- Fondazione Michelangelo
- Medical Research Council
- National Cancer Institute (NCI)
- Fondazione Giovanni Pascale
- University of Pittsburgh
- American Scitech International
- Canadian Cancer Trials Group
- Cancer and Leukemia Group B (CALGB)
- Case Western Reserve University
- Cancer Research UK
- Eastern Cooperative Oncology Group
- Temple University
- University of Washington
- French Innovative Leukemia Organisation
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Gruppo Italiano Studio Linfomi
- Herbert Irving Comprehensive Cancer Center
- Institut Bergonié
- Johns Hopkins University
- +60 more
Organization Involved with Phase 2 Indications (173)
- S*BIO
- 4SC AG
- ADC Therapeutics SARL
- Incyte
- Abbott
- Regeneron
- Spectrum Pharmaceuticals
- Takeda
- Celgene
- Cephalon
- Medarex
- Amgen
- Astellas
- Gilead Sciences
- Schering-Plough
- Pharmacyclics
- Genentech
- MedImmune
- Plexxikon
- Sanofi
- Tanox
- Wyeth
- BioLineRx, Ltd.
- Celldex Therapeutics
- GlaxoSmithKline
- Italfarmaco
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- MethylGene Inc.
- Mirati Therapeutics Inc.
- Polyphor Ltd.
- +143 more
Organization Involved with Phase 1 Indications (31)
- Morphotek
- Arno Therapeutics
- Cortice Biosciences, Inc.
- Fate Therapeutics
- Mundipharma
- Regimmune Inc.
- ImaginAb, Inc.
- TG Therapeutics, Inc.
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- American Society of Clinical Oncology
- Cedars-Sinai Medical Center
- Dartmouth University
- ECOG-ACRIN Cancer Research Group
- McGill University
- University of Kentucky
- University of Southern California
- Wake Forest University
- University of California, Davis
- University of Colorado, Denver
- Cancer Immunotherapy Trials Network
- University of Amsterdam
- Xencor
- South Texas Accelerated Research Therapeutics
- University of North Carolina at Chapel Hill
- University of Wisconsin
- University of Alabama, Birmingham
- Tapestry Pharmaceuticals, Inc.
- Miltenyi Biotec, Inc.
- CLL Global Research Foundation
- Inhibrx, Inc.
- +1 more
Organization Involved with Other Experimental Indications (12)